Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor

Oncotarget

Volumn 3, Issue 2, 2012, Pages 183-194

  Guseva, Natalya V ^a   Rokhlin, Oskar W ^a   Bair, Thomas B ^b   Glover, Rebecca B ^a   Cohen, Michael B ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Androgen receptor; Foxa1; P53; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; FOXA1 PROTEIN, HUMAN; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; CELL PROLIFERATION; CHROMATIN; DRUG ANTAGONISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; PROTEIN BINDING; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863799882     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.449     Document Type: Article

References (36)

1. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nature reviews. 2002; 2: 389-396.
2. Feldman BJ, Feldman D. The development of androgenindependent prostate cancer. Nat Rev Cancer. 2001; 1: 34-45.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nature medicine. 2004; 10: 33-39.
4. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer research. 2002; 62: 1008-1013.
5. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptors in prostate cancer. Endocrine-related cancer. 2002; 9: 155-170.
6. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res. 1995; 1: 1111-1118.
7. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol. 1999; 161: 304-308.
8. Burchardt M, Burchardt T, Shabsigh A, Ghafar M, Chen MW, Anastasiadis A, de la Taille A, Kiss A, Buttyan R. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate. 2001; 48: 225-230.
9. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D. Expression of androgen receptor is negatively regulated by p53. Neoplasia. 2007; 9: 1152-1159.
10. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE, Cohen MB. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene. 2005; 24: 6773-6784.
11. Sanchez R, Nguyen D, Rocha W, White JH, Mader S. Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays. 2002; 24: 244-254.
12. Stender JD, Kim K, Charn TH, Komm B, Chang KC, Kraus WL, Benner C, Glass CK, Katzenellenbogen BS. Genomewide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol. 2010; 30: 3943-3955.
13. Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Molecular cell. 2005; 19: 631-642.
14. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. A hierarchical network of transcription factors governs androgen receptordependent prostate cancer growth. Molecular cell. 2007; 27: 380-392.
15. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Molecular cell. 2002, 9: 601-610.
16. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138: 245-256.
17. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 2008; 132: 958-970.
18. Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A, Rennie PS, Matusik RJ. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol. 2003; 17: 1484-1507.
19. Lupien M, Brown M. Cistromics of hormone-dependent cancer. Endocr Relat Cancer. 2009; 16: 381-389.
20. Ji X, Li W, Song J, Wei L, Liu XS. CEAS: cis-regulatory element annotation system. Nucleic Acids Res. 2006; 34(Web Server issue):W551-554.
21. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y. Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010; 17: 443-454.
22. Guseva NV, Rokhlin OW, Glover RA, Cohen MB. TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status. Cancer Biol Ther. 2011; 12: 80-85.
23. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, de Vere White RW. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer. 1998; 83: 2534-2539.
24. Schulz WA, Burchardt M, Cronauer MV. Molecular biology of prostate cancer. Mol Hum Reprod. 2003; 9: 437-448.
25. Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene. 2004; 23: 3541-3549.
26. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. The New England journal of medicine. 2004; 351: 1488-1490.
27. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocrine reviews. 2004; 25: 276-308.
28. Gao N, Ishii K, Mirosevich J, Kuwajima S, Oppenheimer SR, Roberts RL, Jiang M, Yu X, Shappell SB, Caprioli RM, Stoffel M, Hayward SW, Matusik RJ. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development. 2005; 132: 3431-3443.
29. Crowe AJ, Sang L, Li KK, Lee KC, Spear BT, Barton MC. Hepatocyte nuclear factor 3 relieves chromatin-mediated repression of the alpha-fetoprotein gene. The Journal of biological chemistry. 1999; 274: 25113-25120.
30. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005; 437: 436-439.
31. Tsai WW, Nguyen TT, Shi Y, Barton MC. p53-targeted LSD1 functions in repression of chromatin structure and transcription in vivo. Mol Cell Biol. 2008; 28: 5139-5146.
32. Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Ann Intern Med. 2009; 150: 595-603.
33. Rokhlin OW, Guseva N, Tagiyev A, Knudson CM, Cohen MB. Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis. Oncogene. 2001; 20: 2836-2843.
34. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4: 44-57.
35. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37: 1-13.
36. Rokhlin OW, Guseva NV, Taghiyev AF, Glover RA, Cohen MB. KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer. Cancer Biol Ther. 2010; 9: 224-235.